lutathera
advanced accelerator applications - lutetium (177lu) oxodotreotide - neuroendocrine tumors - other therapeutic radiopharmaceuticals - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep‑nets) in adults.
somatostatin-eumedica 3 mg iv 3mg/vial injection
modern pharmaceutical company belgium - 1 powder ampoule + 1 solvent ampoule (1ml) - injection - 3mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 3 mg iv 3mg/vial injection
modern pharmaceutical company belgium - 1 powder ampoule + 1 solvent ampoule (1ml) - injection - 3mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 0.25 mg iv 0.25mg/vial injection
modern pharmaceutical company belgium - 1 powder vial + 1 solvent ampoule (1ml) - injection - 0.25mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 3 mg iv 3mg/vial injection
modern pharmaceutical company belgium - 1 powder ampoule + 1 solvent ampoule (1ml) - injection - 3mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 0.25 mg iv
1 powder vial + 1 solvent ampoule (1ml) -
somatostatin-eumedica 3 mg iv
1 powder ampoule + 1 solvent ampoule (1ml) -
somatostatin-eumedica 0.25 mg iv 0.25mg/vial injection
modern pharmaceutical company belgium - 1 powder vial + 1 solvent ampoule (1ml) - injection - 0.25mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 3 mg iv 3mg/vial injection
modern pharmaceutical company belgium - 1 powder ampoule + 1 solvent ampoule (1ml) - injection - 3mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 0.25 mg iv
1 powder vial + 1 solvent ampoule (1ml) -